Coegin Pharma (COEGIN) Status Update summary

Recent developments and partnerships

• Entered an agreement with University of Bradford to commercialize pigmentation peptides, focusing on a skin pigmentation peptide.

• Initiated development agreements with a cosmetic company for skin pigmentation and with Scandinavian Biolabs for a hair growth product.

Follicopeptide product overview and clinical results

• Follicopeptide, derived from human osteopontin, is designed for daily topical scalp application.

• Clinical studies show benefits in over 70% of users, with plans to launch as an ingredient in multiple products globally.

Commercialization and launch plans

• Targeting launch in the U.S. and Europe by Q4 2025, with production starting in Q1 2025 and finished product delivery by end of Q3 2025.

• Business dialogues with potential partners have validated the innovation and confirmed strong market demand.

• Focused on identifying experienced partners and scaling up production to meet demand in key markets.